Transposon Therapeutics, Inc.
Clinical trials sponsored by Transposon Therapeutics, Inc., explained in plain language.
-
New drug TPN-101 tested in ALS and dementia patients with C9orf72 gene mutation
Disease control CompletedThis study tested a drug called TPN-101 in 42 people with ALS or frontotemporal dementia caused by a specific gene change (C9orf72). The main goal was to check if the drug is safe and tolerable over 48 weeks. Researchers also looked at how the drug moves in the body and whether i…
Phase: PHASE2 • Sponsor: Transposon Therapeutics, Inc. • Aim: Disease control
Last updated Jun 22, 2026 12:03 UTC
-
New drug tested for rare brain disease PSP
Disease control CompletedThis study tested a drug called TPN-101 in 42 people with progressive supranuclear palsy (PSP), a rare brain disease that affects movement and thinking. The main goal was to see if the drug is safe and tolerable over 48 weeks. Researchers also looked at how the drug moves in the …
Phase: PHASE2 • Sponsor: Transposon Therapeutics, Inc. • Aim: Disease control
Last updated Jun 09, 2026 12:08 UTC